Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation

Full text
Author(s):
Show less -
Arruda, Lucas C. M. ; de Azevedo, Julia T. C. ; de Oliveira, Gislane L. V. ; Scortegagna, Gabriela T. ; Rodrigues, Evandra S. ; Palma, Patricia V. B. ; Brum, Doralina G. ; Guerreiro, Carlos T. ; Marques, Vanessa D. ; Barreira, Amilton A. ; Covas, Dimas T. ; Simoes, Belinda P. ; Voltarelli, Julio C. ; Oliveira, Maria Carolina ; Malmegrim, Kelen C. R.
Total Authors: 15
Document type: Journal article
Source: Clinical Immunology; v. 169, p. 47-57, AUG 2016.
Web of Science Citations: 16
Abstract

High dose immunosuppression followed by autologous hematopoietic stem cell transplantation (AHSCT) induces prolonged clinical remission in multiple sclerosis (MS) patients. However, how patient immune profiles are associated with clinical outcomes has not yet been completely elucidated. In this study, 37 MS patients were assessed for neurological outcomes, thymic function and long-term immune reconstitution after AHSCT. Patients were followed for a mean (SD) of 68.5 (13.9) months post-transplantation and were retrospectively clustered into progression- and non-progression groups, based on Expanded Disease Status Scale (EDSS) outcomes at last visit. After AHSCT, both patient groups presented increased regulatory T-cell subset counts, early expansion of central- and effector-memory CD8(+) T-cells and late thymic reactivation. However, the non-progression group presented early expansion of PD-1 CD8(+) T-cells and of PD-1-expressing CD19(+) B-cells. Here, we suggest that along with increased numbers of regulatory T-cell subsets, PD-1 inhibitory signaling is one possible immunoregulatory mechanism by which AHSCT restores immune tolerance in MS patients. (C) 2016 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 08/57877-3 - National Institute of Science and Technology in Cell Therapy
Grantee:Roberto Passetto Falcão
Support type: Research Projects - Thematic Grants
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC